ZLNA.OL

Healthcare Biotechnology

Zelluna ASA

NOK 19.65

+0.60 +3.15% today

Price History

Not enough data

Key Stats

Market Cap

586.76M

Avg Volume

59,735

EPS

-NOK 4.90

52W High

NOK 35.80

52W Low

NOK 8.20

Div. Yield

0.0%

Valuation

Forward P/E

-5.27

P/B Ratio

7.70

P/S Ratio

73344.88

EV/EBITDA

-4.66

EV/Revenue

62886.65

Margins

Gross Margin 100.0%

Operating Margin (1383137.5%)

Net Margin 0.0%

EBITDA Margin 0.0%

Growth & Returns

Return on Equity

(115.4%)

Return on Assets

(60.0%)

Liquidity & Leverage

Current Ratio

12.13

Quick Ratio

11.93

Debt / Equity

0.01

Total Cash

86.24M

Total Debt

1.06M

About

Zelluna ASA, a clinical-stage biotechnology company, engages in the development of T-cell receptor guided natural killer cell therapies in Norway. It develops ZI-MA4-1 which is in Phase I clinical trial for the treatment of non-small cell lung cancer, ovarian, and head and neck synovial sarcoma; ZI-KL1-1 which is in preclinical trial for the treatment of breast, gastric, lung, pancreatic, and cervix cancers; and ZI-PR-1 which is in discovery stage for the treatment of solid tumors. The company was incorporated in 2016 and is headquartered in Oslo, Norway.

zelluna.com